Molecular Partners AG ADR - Asset Resilience Ratio
Molecular Partners AG ADR (MOLN) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Molecular Partners AG ADR working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Molecular Partners AG ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Molecular Partners AG ADR's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Molecular Partners AG ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Molecular Partners AG ADR for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Molecular Partners AG ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Molecular Partners AG ADR Industry Peers by Asset Resilience Ratio
Compare Molecular Partners AG ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Molecular Partners AG ADR (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.19% | $10.40 Million | $102.11 Million | -43.78pp |
| 2024-12-31 | 53.97% | $85.56 Million | $158.53 Million | -6.31pp |
| 2023-12-31 | 60.29% | $119.58 Million | $198.35 Million | -1.18pp |
| 2022-12-31 | 61.47% | $161.20 Million | $262.26 Million | +26.14pp |
| 2021-12-31 | 35.33% | $61.00 Million | $172.67 Million | +14.00pp |
| 2020-12-31 | 21.33% | $40.00 Million | $187.55 Million | +2.87pp |
| 2019-12-31 | 18.46% | $19.37 Million | $104.94 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $155.16 Million | -- |
| 2017-12-31 | 6.75% | $9.74 Million | $144.42 Million | -9.81pp |
| 2016-12-31 | 16.56% | $30.49 Million | $184.10 Million | +7.44pp |
| 2015-12-31 | 9.13% | $20.02 Million | $219.40 Million | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more